Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 5/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 6/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.35 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205529 | 0.89 | MMP1 (0.45) | MMP13MMP2ADAM17MMP1TACR1 | |
| SCHEMBL7200507 | 0.89 | MMP13 (0.45) | CARM1PRMT6MMP13MMP2ADAM17 | |
| SCHEMBL7208003 | 0.88 | ALDH1A1 (0.41) | MMP13MMP2ADAM17MMP1TACR1 | |
| SCHEMBL7200956 | 0.87 | MMP2 (0.46) | CARM1PRMT6MMP13MMP2ADAM17 | |
| SCHEMBL7201688 | 0.86 | MMP13 (0.43) | CARM1PRMT6MMP13MMP2ADAM17 | |
| SCHEMBL7204151 | 0.85 | MMP13 (0.51) | CARM1PRMT6MMP13MMP2MMP1 | |
| SCHEMBL7203079 | 0.84 | HTR2C (0.47) | MMP13MMP2P2RX7ADAM10 | |
| SCHEMBL7199718 | 0.84 | CARM1 (0.44) | CARM1PRMT6MMP13MMP2ADAM17 | |
| SCHEMBL7202583 | 0.83 | ADAM17 (0.40) | MMP13MMP2ADAM17MMP1PKM | |
| SCHEMBL7205543 | 0.82 | MMP13 (0.42) | CARM1PRMT6MMP13MMP2ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | CARM1 1408/4885PRMT6 1840/4885MMP13 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.